Kalaris Therapeutics (formerly AlloVir) Funding: $50M Raised

Kalaris Therapeutics (formerly AlloVir) is based in Palo Alto, CA. It has raised $50M in total funding. Latest round: Series B.

Kalaris Therapeutics (formerly AlloVir) funding overview

Kalaris Therapeutics (formerly AlloVir) is based in Palo Alto, CA. Kalaris Therapeutics (formerly AlloVir) has raised $50M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in September 2025. The round record for Kalaris Therapeutics (formerly AlloVir) runs through 2025; nothing later has been disclosed.

Kalaris Therapeutics (formerly AlloVir) at a glance

Total raised
$50M
Latest round
Series B
Latest round date
September 2025
Headquarters
Palo Alto, CA

Frequently asked about Kalaris Therapeutics (formerly AlloVir) funding

How much has Kalaris Therapeutics (formerly AlloVir) raised?
Kalaris Therapeutics (formerly AlloVir) has raised $50M in total disclosed funding across the rounds on record.
Who has invested in Kalaris Therapeutics (formerly AlloVir)?
No investors are named on the public record for Kalaris Therapeutics (formerly AlloVir) yet.
What was the latest Kalaris Therapeutics (formerly AlloVir) funding round?
The most recent disclosed round is a Series B, announced in September 2025.
Where is Kalaris Therapeutics (formerly AlloVir) based?
Kalaris Therapeutics (formerly AlloVir) is based in Palo Alto, CA.
When did Kalaris Therapeutics (formerly AlloVir) last raise?
The last disclosed Kalaris Therapeutics (formerly AlloVir) round closed in September 2025 at Series B.

Round data for Kalaris Therapeutics (formerly AlloVir) is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Palo Alto and backer lists below.

Companies related to Kalaris Therapeutics (formerly AlloVir) (18)

Browse related funding lists (5)

Company funding database · Investor directory · Founder database · Mega-rounds 2026